Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON MARC SCHOENFELD

Allopathic & Osteopathic Physicians Dermatology MOHS-Micrographic Surgery

NPI
1942647078
CMS profile
1102061
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$5,930.87

152 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,000.32 149
Consulting Fee $2,800.00 1
Travel and Lodging $130.55 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON MARC SCHOENFELD

NPI 1942647078 · CMS profile ID 1102061

Allopathic & Osteopathic Physicians / Dermatology / MOHS-Micrographic Surgery

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942647078?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON MARC SCHOENFELD, NPI 1942647078, CMS profile ID 1102061. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942647078?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JASON MARC SCHOENFELD, NPI 1942647078, CMS profile ID 1102061. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942647078?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JASON MARC SCHOENFELD, NPI 1942647078, CMS profile ID 1102061, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 152 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1942647078?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

152 matching records · $5,930.87 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 152 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 152.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Arcutis Biotherapeutics, Inc. $23.1809/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044734309 CMS
PFIZER INC. $13.2309/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050699945 CMS
AbbVie Inc. $17.5908/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870511 CMS
AbbVie Inc. $1.4108/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870503 CMS
AbbVie Inc. $17.2408/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870507 CMS
Janssen Biotech, Inc. $19.5208/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502489 CMS
Regeneron Healthcare Solutions, Inc. $124.9908/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999421435 CMS
GENZYME CORPORATION $12.5208/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050270035 CMS
Novartis Pharmaceuticals Corporation $19.3708/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993273439 CMS
Janssen Biotech, Inc. $22.9708/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502553 CMS
Janssen Biotech, Inc. $1.5608/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502561 CMS
AbbVie Inc. $21.8508/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870499 CMS
Lilly USA, LLC $8.5607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031489387 CMS
Lilly USA, LLC $13.7107/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031612281 CMS
Lilly USA, LLC $6.8007/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031670757 CMS
Regeneron Healthcare Solutions, Inc. $20.4407/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999421431 CMS
Incyte Corporation $28.5807/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044319277 CMS
Janssen Biotech, Inc. $24.5407/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502545 CMS
AbbVie Inc. $13.9607/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870495 CMS
AbbVie Inc. $24.6107/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870491 CMS
Janssen Biotech, Inc. $32.0707/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502522 CMS
Novartis Pharmaceuticals Corporation $34.0307/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993273433 CMS
Janssen Biotech, Inc. $21.8006/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502657 CMS
GENZYME CORPORATION $12.2206/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050269991 CMS
AbbVie Inc. $20.1906/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870483 CMS
AbbVie Inc. $1.0806/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870487 CMS
GENZYME CORPORATION $27.3006/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050269987 CMS
Arcutis Biotherapeutics, Inc. $21.9706/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044734321 CMS
PFIZER INC. $22.3106/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050350013 CMS
Janssen Biotech, Inc. $34.0606/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502585 CMS
AbbVie Inc. $22.7406/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870479 CMS
GENZYME CORPORATION $8.2306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050269975 CMS
Janssen Biotech, Inc. $2.8906/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502675 CMS
Novartis Pharmaceuticals Corporation $18.1206/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993273429 CMS
Helsinn Therapeutics (U.S.), Inc. $18.2406/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058020643 CMS
LEO Pharma Inc. $19.3406/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053525867 CMS
Janssen Biotech, Inc. $29.3006/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502667 CMS
Janssen Biotech, Inc. $25.3906/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502601 CMS
Sun Pharmaceutical Industries Inc. $32.1506/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053867583 CMS
Janssen Biotech, Inc. $28.9806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502641 CMS
Amgen Inc. $21.8505/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020595831 CMS
Lilly USA, LLC $28.0805/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031555744 CMS
Janssen Biotech, Inc. $20.9305/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988502683 CMS
Regeneron Healthcare Solutions, Inc. $15.0205/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999421425 CMS
Regeneron Healthcare Solutions, Inc. $0.6705/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999421419 CMS
AbbVie Inc. $17.4205/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870475 CMS
AbbVie Inc. $6.8905/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870471 CMS
AbbVie Inc. $19.4405/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998870467 CMS
E.R. Squibb & Sons, L.L.C. $15.4205/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015722411 CMS
GENZYME CORPORATION $8.2205/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050269965 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,512.88 93
PY2020 $1,419.67 82
PY2021 $2,187.04 135
PY2022 $2,812.02 168
PY2023 $5,930.87 152
PY2024 $2,869.87 161
PY2025 $3,471.59 179

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $753,829.06 67
PY2024 Principal investigator $165,549.03 29
PY2023 Principal investigator $19,975.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $44,182.00 12/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422117
Principal investigator 1 SANOFI US SERVICES INC. $4,242.40 12/22/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132907
Principal investigator 1 SANOFI US SERVICES INC. $7,833.60 12/15/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132886
Principal investigator 1 ABBVIE INC. $183.33 12/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202529708
Principal investigator 1 ABBVIE INC. $700.65 12/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202529710
Principal investigator 1 SANOFI US SERVICES INC. $3,225.10 12/08/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132871
Principal investigator 1 ABBVIE INC. $35,815.62 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527458
Principal investigator 1 ABBVIE INC. $7,660.24 12/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202527460
Principal investigator 1 SANOFI US SERVICES INC. $5,237.82 11/24/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132883
Principal investigator 1 SANOFI US SERVICES INC. $9,516.40 11/17/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132864
Principal investigator 1 ABBVIE INC. $23,239.15 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522653
Principal investigator 1 ABBVIE INC. $26,907.23 11/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202520883
Principal investigator 1 Janssen Research & Development, LLC $20,340.00 10/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422149
Principal investigator 1 SANOFI US SERVICES INC. $43,495.50 10/20/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132847
Principal investigator 1 SANOFI US SERVICES INC. $2,327.22 10/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132837
Principal investigator 1 ABBVIE INC. $1,075.68 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514153
Principal investigator 1 ABBVIE INC. $20,675.41 10/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202514155
Principal investigator 1 Janssen Research & Development, LLC $4,156.00 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422136
Principal investigator 1 SANOFI US SERVICES INC. $3,718.60 09/22/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132815
Principal investigator 1 SANOFI US SERVICES INC. $6,552.00 09/15/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132807
Principal investigator 1 Janssen Research & Development, LLC $33,814.00 09/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422098
Principal investigator 1 Janssen Research & Development, LLC $8,370.00 09/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422145
Principal investigator 1 SANOFI US SERVICES INC. $1,260.00 09/08/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132777
Principal investigator 1 ABBVIE INC. $13,539.78 09/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509932
Principal investigator 1 ABBVIE INC. $6,000.00 08/26/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202505853
Principal investigator 1 SANOFI US SERVICES INC. $562.00 08/25/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132812
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 08/18/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132768
Principal investigator 1 ABBVIE INC. $4,242.50 08/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202503169
Principal investigator 1 Janssen Research & Development, LLC $35,715.00 07/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422122
Principal investigator 1 SANOFI US SERVICES INC. $162.00 07/28/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132762
Principal investigator 1 ABBVIE INC. $6,000.00 07/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202499102
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132730
Principal investigator 1 SANOFI US SERVICES INC. $19,529.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132743
Principal investigator 1 SANOFI US SERVICES INC. $17,350.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226132752
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132756
Principal investigator 1 ABBVIE INC. $3,798.31 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202494823
Principal investigator 1 ABBVIE INC. $21,417.25 07/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202495457
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 07/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132748
Principal investigator 1 Janssen Research & Development, LLC $23,626.00 06/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422160
Principal investigator 1 ABBVIE INC. $1,135.07 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202489579
Principal investigator 1 ABBVIE INC. $5,437.08 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202489809
Principal investigator 1 ABBVIE INC. $7,427.74 06/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489811
Principal investigator 1 ABBVIE INC. $1,123.20 06/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202487297
Principal investigator 1 Janssen Research & Development, LLC $28,946.00 05/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175422154
Principal investigator 1 SANOFI US SERVICES INC. $17,449.00 05/27/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) No dispute reported 06/30/2026 1226132699
Principal investigator 1 ABBVIE INC. $745.92 05/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202484317
Principal investigator 1 ABBVIE INC. $23,968.40 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482829
Principal investigator 1 ABBVIE INC. $8,084.59 05/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481479
Principal investigator 1 SANOFI US SERVICES INC. $270.95 05/05/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132677
Principal investigator 1 ABBVIE INC. $11,550.58 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202470376
Principal investigator 1 ABBVIE INC. $7,632.20 04/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202470379
Principal investigator 1 SANOFI US SERVICES INC. $24,401.20 04/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132647
Principal investigator 1 SANOFI US SERVICES INC. $8,419.85 04/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132660
Principal investigator 1 SANOFI US SERVICES INC. $8,415.30 04/02/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132672
Principal investigator 1 SANOFI US SERVICES INC. $1,155.00 03/24/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment No dispute reported 06/30/2026 1226132656
Principal investigator 1 ABBVIE INC. $11,090.60 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460703
Principal investigator 1 ABBVIE INC. $689.85 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202456821
Principal investigator 1 ABBVIE INC. $13,748.65 03/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202457649
Principal investigator 1 SANOFI US SERVICES INC. $8,954.90 02/24/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132582
Principal investigator 1 ABBVIE INC. $16,356.95 02/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202448262
Principal investigator 1 ABBVIE INC. $6,106.45 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444937
Principal investigator 1 SANOFI US SERVICES INC. $16,100.00 02/04/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults No dispute reported 06/30/2026 1226132596
Principal investigator 1 SANOFI US SERVICES INC. $7,834.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132605
Principal investigator 1 SANOFI US SERVICES INC. $18,023.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
A Phase 2, Randomized, Double-blind, Placebo--controlled, Parallel Group, 3-arm, Multinational, Multicenter, Proof-of-concept Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Adult Participants With Severe Alopecia Areata No dispute reported 06/30/2026 1226132609
Principal investigator 1 SANOFI US SERVICES INC. $18,256.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Philadelphia Llc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226132613
Principal investigator 1 Eli Lilly and Company $2,000.00 01/10/2025 Non-covered Recipient Entity
WCG CLINICAL INC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187891786
Principal investigator 1 ABBVIE INC. $4,036.79 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH PHILADELPHIA LLC
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202434767